HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

High blood pressure - also known as hypertension - can lead to severe cardiovascular disease, heart attack or stroke. Six in ...

As well as shedding pounds and controlling diabetes, Ozempic and Wegovy can help you drink less, researchers suggest ...

Apple cider vinegar is fermented juice made from apples. It may be useful in blood sugar management, weight loss, and ...

For the first time a semaglutide weight loss drug has been approved for use in Australia to also treat cardiovascular disease ...

Body mass index, or BMI, is computed by dividing your weight by your height (squared). It is generally used to help you determine your risk of having various types of health problems as you age. Being ...

They are prone to become overweight or obese adults. Sleep deprivation can disrupt hormones that regulate appetite, leading to overeating. Ensure children get 9-12 hours of sleep per night ...

A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based ...

The Allurion swallowable intragastric balloon offers a safe, effective and minimally invasive method of losing weight.

Based on the results, Novo Nordisk is now planning further clinical development of amycretin in adults with overweight or obesity. Amycretin is a unimolecular long-acting GLP-1 and amylin receptor ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...